Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-137279

Published: 2020

Journal Articles

Pneumococcal Vaccination (PCV13) Prior to Initiation of Immunosuppressive Therapy in Patients with Hematological Malignancies Is Associated with Decrease Morbidity and Decrease Hospitalizations

Regina Draliuk, MA, Iveta Mintsman, MD, Alla Shnaider, Shuras Viky, Rotem Benami, Noga Salem, Olga Valkovsky, MD, Mouna Ballan Haj, MD, Evelyne Shabad, MD, Antonio Kotler, MD, Elena Mishchenko, MD, Meir Preis, MD PhD

Blood (2018) 132 (Supplement 1): 5919.

https://doi.org/10.1182/blood-2018-99-118483

Published: 2018

Journal Articles

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Noa Lavi, MD, Maya Koren-Michowitz, MD, Avi Leader, MD, Adi Shacham-Abulafia, MD, Shirley Shapira, MD, Najib Dally, MD, Evgeni Chubar, MD, Elena Mishchenko, MD, Martin H. Ellis, MD

Blood (2015) 126 (23): 4081.

https://doi.org/10.1182/blood.V126.23.4081.4081

Published: 2015

Journal Articles

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Martin H. Ellis, MD, Noa Lavi, MD, Elena Mishchenko, MD, Najib Dally, MD, David Lavie, MD, Anna Courevitch, MD, Odit Gutwein, MD, Shlomo Bulvik, MD, Andrei Braester, MD, Evgeni Chubar, MD, Sigal Tavor, MD, Adrian Duek, MD, Ilya Kirgner, MD, Maya Koren-Michowitz, MD

Blood (2014) 124 (21): 1830.

https://doi.org/10.1182/blood.V124.21.1830.1830

Published: 2014

Journal Articles

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Ruben A. Mesa, MD, Jorge E. Cortes, MD, Francisco Cervantes, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Professor, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Florence Joulain, MSc, Sheikh Usman Iqbal, MD MPH MBA, Claire N Harrison, DM, FRCP, FRCPath

Blood (2013) 122 (21): 4061.

https://doi.org/10.1182/blood.V122.21.4061.4061

Published: 2013

Journal Articles

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Claire N Harrison, DM, FRCP, FRCPath, Jorge E. Cortes, MD, Francisco Cervantes, MD, Ruben A. Mesa, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Guozhi Gao, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 393.

https://doi.org/10.1182/blood.V122.21.393.393

Published: 2013

NARROW

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Pneumococcal Vaccination (PCV13) Prior to Initiation of Immunosuppressive Therapy in Patients with Hematological Malignancies Is Associated with Decrease Morbidity and Decrease Hospitalizations

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Email alerts

ASH Publications

American Society of Hematology

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Pneumococcal Vaccination (PCV13) Prior to Initiation of Immunosuppressive Therapy in Patients with Hematological Malignancies Is Associated with Decrease Morbidity and Decrease Hospitalizations

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only